SCHEMBL959954

SCHEMBL959954

COc1ccc2c(c1)CC[C@@H]1[C@@H]2CC[C@]2(C)C(=O)CC[C@@H]12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B1 P14061 4/20 1.00
LMNA P02545 3/20 1.00
MAPT P10636 2/20 1.00
RECQL P46063 1/20 1.00
SMN1; SMN2 Q16637 1/20 1.00
STS P08842 7/20 0.78
ESR1 P03372 3/20 0.76
ESR2 Q92731 2/20 0.76
KDM4E B2RXH2 2/20 0.76
CA1 P00915 2/20 0.76
CA2 P00918 2/20 0.76
CA9 Q16790 2/20 0.76
ABCC4 O15439 1/20 0.76
CYP2C9 P11712 1/20 0.76
ABCC1 P33527 1/20 0.76
SLCO1B1 Q9Y6L6 1/20 0.76
CA4 P22748 1/20 0.76
CA6 P23280 1/20 0.76
CYP3A4 P08684 3/20 0.72
CYP19A1 P11511 2/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15308964 1.00 HSD17B1 (1.00) HSD17B1LMNAMAPTRECQLSMN1; SMN2
SCHEMBL12441050 1.00 HSD17B1 (1.00) HSD17B1LMNAMAPTRECQLSMN1; SMN2
SCHEMBL5017878 1.00 HSD17B1 (1.00) HSD17B1LMNAMAPTRECQLSMN1; SMN2
SCHEMBL5682139 1.00 HSD17B1 (1.00) HSD17B1LMNAMAPTRECQLSMN1; SMN2
SCHEMBL4570835 1.00 HSD17B1 (1.00) HSD17B1LMNAMAPTRECQLSMN1; SMN2
SCHEMBL10079402 1.00 HSD17B1 (1.00) HSD17B1LMNAMAPTRECQLSMN1; SMN2
SCHEMBL5677806 1.00 HSD17B1 (1.00) HSD17B1LMNAMAPTRECQLSMN1; SMN2
SCHEMBL18658723 1.00 HSD17B1 (1.00) HSD17B1LMNAMAPTRECQLSMN1; SMN2
Ethylene SCHEMBL11570544 0.98 HSD17B1 (0.95) HSD17B1LMNAMAPTRECQLSMN1; SMN2
SCHEMBL3872024 0.93 HSD17B1 (0.87) HSD17B1LMNAMAPTRECQLSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 316 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111032024-A Bioerodible drug delivery implant 赫拉健康解决方案公司 2020-04-17 CN claimed
EP-1831144-B1 A NEW PROCESS FOR THE PREPARATION OF PHENOLIC HYDROXY-SUBSTITUTED COMPOUNDS RICHTER GEDEON NYRT (HU) 2011-08-17 EP claimed
US-7973185-B2 Process for the preparation of phenolic hydroxy-substituted compounds RICHTER GEDEON NYRT. (HU) 2011-07-05 US claimed
US-20080039643-A1 Process for the Preparation of Phenolic Hydroxy-Substituted Compounds RICHTER GEDEON VEGYESZETI GYAR RT. (HU) 2008-02-14 US claimed
EP-1831144-A2 A NEW PROCESS FOR THE PREPARATION OF PHENOLIC HYDROXY-SUBSTITUTED COMPOUNDS RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) 2007-09-12 EP claimed
WO-2006061666-A2 A NEW PROCESS FOR THE PREPARATION OF PHENOLIC HYDROXY-SUBSTITUTED COMPOUNDS Richter Gedeon Vegyészeti Gyár Rt. (HU) 2006-06-15 WO claimed
CN-1036833-C Contraceptive regimen AKZO NV (NL) 1997-12-31 CN claimed
EP-0182808-A1 17 a?$g(b)-HYDROXY-7$g(a)-METHYL-D-HOMO-19-NORANDROST-4,16-DIENE-3-ONE AND THE 17-ESTERS THEREOF: METHODS OF PREPARATION AND USES SRI INTERNATIONAL (US) 1986-06-04 EP claimed
WO-1985005361-A1 17abeta-HYDROXY-7alpha-METHYL-D-HOMO-19-NORANDROST-4,16-DIENE-3-ONE AND THE 17-ESTERS THEREOF: METHODS OF PREPARATION AND USES SRI INTERNATIONAL (US) 1985-12-05 WO claimed
EP-0037973-B1 PROCESS FOR THE SYNTHESIS OF ESTRONE OR ESTRONE DERIVATIVES HOECHST AKTIENGESELLSCHAFT (DE) 1984-05-30 EP claimed
JP-55020746-A None JP disclosed
JP-5178884-A None JP disclosed
CN-122055369-A Bridged tricyclic carbamoyl pyridone compounds and uses thereof 吉利德科学公司 2026-05-15 CN disclosed
CN-122055373-A Bridged tricyclic carbamoyl pyridone compounds and uses thereof 吉利德科学公司 2026-05-15 CN disclosed
CN-114245807-B FLT3L-FC fusion proteins and methods of use 吉利德科学公司 2025-05-02 CN disclosed
US-3960842-A Process for the preparation of 17β-oxalyl steroids SCHERING AKTIENGESELLSCHAFT (DT) 1976-06-01 US disclosed
US-3956348-A Steroid ether splitting SCHERING AKTIENGESELLSCHAFT (DT) 1976-05-11 US disclosed
US-3952018-A 15-Oxasteroids HOFFMANN-LA ROCHE INC. (US) 1976-04-20 US disclosed
US-3933870-A Synthesis of A-ring aromatic steroids HOFFMANN-LA ROCHE INC. (US) 1976-01-20 US disclosed
US-3932519-A 7,7A-Dihydro-4-[2-(3-alkoxyphenyl)-2-hydroxyethyl]-7a-alkyl-1, 5(6H)-indandiones,3,4,8,8a-tetrahydro-5-[2-(3-alkoxyphenyl)-2-hydroxyethyl]-8a-alkyl-1,6(7H)-naphthalenediones and processes for the preparation thereof utilizing asymmetric induction HOFFMANN-LA ROCHE INC. (US) 1976-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039643-A1 Process for the Preparation of Phenolic Hydroxy-Substituted Compounds NR3C2, CYP21A2, NR5A1 HSD17B1 23/4885LMNA 3652/4885MAPT 4563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.